Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05825300 · ClinicalTrials.gov registry record · NA

Encouraging Blood Donation in Patients With a Blood Type in Short Supply - Part 2

A NA study of Behavior, Health, sponsored by Geisinger Clinic.

Completed
Registry status
NA
Development phase
40,486
Enrollment target
1
Study location

NCT05825300 is a NA study of Behavior, Health that has completed, run by Geisinger Clinic. The registered enrollment target is 40,486 participants, above the 13,767-participant average among 20 other Behavior, Health trials with a reported enrollment target (194% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05825300, a NA study of Behavior, Health, has completed, sponsored by Geisinger Clinic.

COMPLETED
Registry status
NA
Development phase
40,486 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to test whether emails that inform patients they have a blood type in need are more effective at encouraging patients to schedule and attend blood donation appointments, compared to email messages that do not mention the patient has a blood type in need.

Conditions Studied

Interventions

  • BEHAVIORAL Email message
  • BEHAVIORAL Social responsibility

Study Locations (1)

Pennsylvania

  • Geisinger Clinic - Danville

Trial Details

FieldValue
Enrollment Target 40,486 participants
Start Date 2023-04-10
Est. Completion 2023-07-03
Phase NA

Sponsor

Geisinger Clinic

107 total trials

What the Registry Record Tells You About NCT05825300

The ClinicalTrials.gov registry entry for NCT05825300 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40,486 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 13,767-participant average among 20 other Behavior, Health trials with a reported enrollment target (194% higher). The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Behavior, Health appearing as the primary indexed condition, and to 2 interventions - of which Email message is the first listed.

NCT05825300 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05825300 about?

NCT05825300 is a clinical study titled "Encouraging Blood Donation in Patients With a Blood Type in Short Supply - Part 2". The goal of this study is to test whether emails that inform patients they have a blood type in need are more effective at encouraging patients to schedule and attend blood donation appointments, compared to email messages that do not mention the patient has a blood type in need.

What is the current status of trial NCT05825300?

This trial is currently completed. It is a NA study. The enrollment target is 40,486 participants. The study started on 2023-04-10. Estimated completion is 2023-07-03.

What conditions does trial NCT05825300 study?

This clinical trial studies the following conditions: Behavior, Health.

What interventions are being tested in trial NCT05825300?

The interventions under investigation include: Email message (BEHAVIORAL), Social responsibility (BEHAVIORAL).

Who is sponsoring clinical trial NCT05825300?

This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05825300 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Behavior, Health

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.